Literature DB >> 2993530

Prognostic significance of serum alpha 1-acid glycoprotein in patients with glioblastoma multiforme: a preliminary communication.

H Matsuura, S Nakazawa.   

Abstract

The relationship between the levels of serum acute phase reactant proteins (alpha 1-acid glycoprotein, alpha 1-antitrypsin, haptoglobin) was investigated in patients with glioblastoma multiforme in relation to their prognosis. Alpha 1-acid glycoprotein was higher in the patients who died within one year after admission than in those with a longer survival time. It is suggested that serum alpha 1-acid glycoprotein profiles provide prognostic information in patients with glioblastoma multiforme.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2993530      PMCID： PMC1028458          DOI： 10.1136/jnnp.48.8.835

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  18 in total

1.  Interactions of alpha1-acid glycoprotein with the immune system. I. Purification and effects upon lymphocyte responsiveness.

Authors:  K M Chiu; R F Mortensen; A P Osmand; H Gewurz
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

2.  Immune responses in patients with gliomas.

Authors:  W H Brooks; H D Caldwell; R H Mortara
Journal:  Surg Neurol       Date:  1974-11

Review 3.  Tumors and serum glycoproteins. The 'symbodies'.

Authors:  C A Apffel; J H Peters
Journal:  Prog Exp Tumor Res       Date:  1969

4.  Acute phase reactant proteins in prostatic cancer.

Authors:  A M Ward; E H Cooper; A L Houghton
Journal:  Br J Urol       Date:  1977-10

5.  Elevated alpha1-Antitrypsin serum levels in lung cancer patients.

Authors:  C C Harris; A Primack; M H Cohen
Journal:  Cancer       Date:  1974-08       Impact factor: 6.860

6.  Plasma alpha-1-antitrypsin levels in early and late carcinoma of the cervix.

Authors:  A L Latner; G A Turner; M M Lamin
Journal:  Oncology       Date:  1976       Impact factor: 2.935

7.  Serum alpha-1-acid glycoprotein as an index of dissemination in breast cancer.

Authors:  J G Roberts; J W Keyser; M Baum
Journal:  Br J Surg       Date:  1975-10       Impact factor: 6.939

8.  Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer.

Authors:  R Samak; R Edelstein; L Israel
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

9.  Alpha-globulins in the surveillance of colorectal cancer.

Authors:  E H Cooper; R Turner; A Geekie; A M Neville; J C Goligher; N G Graham; G R Giles; R Hall; W A Macadam
Journal:  Biomedicine       Date:  1976-06

10.  Effects of C-reactive protein on the lymphoid system. II. Inhibition of mixed lymphocyte reactivity and generation of cytotoxic lymphocytes.

Authors:  R F Mortensen; H Gewurz
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422
View more
  10 in total

1.  Comparison of lymphokine-activated killer activities between thymocytes and splenocytes in rats with brain tumors.

Authors:  H Matsuura; H Imaya
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Immunosuppressive acidic protein in patients with brain tumours: a preliminary report.

Authors:  K Kikuchi; H Gotoh; M Kowada
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

3.  A correlation between serum immunosuppressive acidic protein and altered immunocompetence in patients with brain tumours.

Authors:  K Kikuchi; H Gotoh; M Kowada
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

4.  Serum albumin and survival in glioblastoma multiforme.

Authors:  Nicholas Borg; Mathew R Guilfoyle; David C Greenberg; Colin Watts; Simon Thomson
Journal:  J Neurooncol       Date:  2011-03-16       Impact factor: 4.130

5.  Liquid biopsies in patients with diffuse glioma.

Authors:  Myron G Best; Nik Sol; Sebastiaan Zijl; Jaap C Reijneveld; Pieter Wesseling; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2015-02-27       Impact factor: 17.088

6.  Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples.

Authors:  Natalia A Petushkova; Victor G Zgoda; Mikhail A Pyatnitskiy; Olesya V Larina; Nadezhda B Teryaeva; Alexander A Potapov; Andrey V Lisitsa
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

7.  Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model.

Authors:  Linpei Zhang; Yuqiu Li; Wenshu Meng; Yanying Ni; Youhe Gao
Journal:  Cancer Med       Date:  2019-05-15       Impact factor: 4.452

8.  Investigating Glioblastoma Multiforme Sub-Proteomes: A Computational Study of CUSA Fluid Proteomic Data.

Authors:  Fabiana Moresi; Diana Valeria Rossetti; Federica Vincenzoni; Giorgia Antonia Simboli; Giuseppe La Rocca; Alessandro Olivi; Andrea Urbani; Giovanni Sabatino; Claudia Desiderio
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

9.  Identification of differentially expressed serum proteins in gastric adenocarcinoma.

Authors:  Yashwanth Subbannayya; Sartaj Ahmad Mir; Santosh Renuse; Srikanth S Manda; Sneha M Pinto; Vinuth N Puttamallesh; Hitendra Singh Solanki; H C Manju; Nazia Syed; Rakesh Sharma; Rita Christopher; M Vijayakumar; K V Veerendra Kumar; T S Keshava Prasad; Girija Ramaswamy; Rekha V Kumar; Aditi Chatterjee; Akhilesh Pandey; Harsha Gowda
Journal:  J Proteomics       Date:  2015-05-05       Impact factor: 4.044

10.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.